Amirghofran Zahra, Jalali Seyed Amir, Hosseini Seyed Vahid, Vasei Mohammad, Sabayan Behnam, Ghaderi Abbas
Immunology Department, Medical School, Shiraz University of Medical Science, 71345-1798, Shiraz, Iran.
J Gastrointest Cancer. 2008;39(1-4):73-8. doi: 10.1007/s12029-009-9062-2. Epub 2009 Mar 31.
It has been shown that CD44 may be associated with poor prognosis in various human malignancies. This study was designed to investigate and compare the prognostic relevance and clinical value of soluble forms of CD44 and its variant v6 (CD44v6) and their tissue expression in colorectal carcinoma.
Serum levels of pre- and postoperative CD44 and CD44v6 molecules were evaluated in 37 colorectal cancer patients and compared to healthy individuals.
The serum levels of soluble CD44 and CD44v6 showed no significant decrease after surgical resection of the tumor (p = 0.5). Both CD44 and CD44v6 serum levels either before or after surgery were significantly higher in patients than in normal individuals (p < 0.001). The serum level of CD44v6 molecule was higher in patients with lymph node metastasis than other patients (p = 0.05) implying the role of this molecule in tumor progression. Immunohistochemical staining showed expression of CD44 in 14.3% and CD44v6 in 42.9% of the tumor samples. The expression of CD44v6 was associated with metastatic involvement of lymph nodes (p = 0.03). CD44v6 expression was positively correlated with its level in the serum of patients (p = 0.04).
Results of this study showed that CD44v6 expression level either in the soluble form or in the cell membrane is associated with tumor metastasis indicating the importance of this molecule in progression of colorectal carcinoma. The serum levels of soluble CD44 as well as CD44v6 might be useful markers for tumor screening.
已有研究表明,CD44可能与多种人类恶性肿瘤的不良预后相关。本研究旨在调查和比较CD44及其变体v6(CD44v6)的可溶性形式的预后相关性和临床价值及其在结直肠癌中的组织表达。
评估了37例结直肠癌患者术前和术后血清中CD44和CD44v6分子的水平,并与健康个体进行比较。
肿瘤手术切除后,可溶性CD44和CD44v6的血清水平无显著下降(p = 0.5)。患者术前和术后CD44和CD44v6的血清水平均显著高于正常个体(p < 0.001)。有淋巴结转移的患者血清中CD44v6分子水平高于其他患者(p = 0.05),这意味着该分子在肿瘤进展中起作用。免疫组织化学染色显示,14.3%的肿瘤样本中表达CD44,42.9%的肿瘤样本中表达CD44v6。CD44v6的表达与淋巴结转移有关(p = 0.03)。CD44v6的表达与其在患者血清中的水平呈正相关(p = 0.04)。
本研究结果表明,可溶性形式或细胞膜形式的CD44v6表达水平与肿瘤转移有关,表明该分子在结直肠癌进展中的重要性。可溶性CD44以及CD44v6的血清水平可能是有用的肿瘤筛查标志物。